intrahepatic%20cholestasis
INTRAHEPATIC CHOLESTASIS
Cholestasis is bile formation and/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.

Intrahepatic%20cholestasis Signs and Symptoms

Introduction

  • Any condition that causes bile formation and/or bile flow impairment that may lead to:
    • Retention of conjugated bilirubin and its regurgitation into serum
    • Increased serum concentration of unconjugated bilirubin
    • Increased bile salts

Etiology

Extrahepatic Cholestasis

  • Cholestasis that develops from mechanical blockage in the duct system or hepatocellular defects
  • It may be caused by stones, tumors, cysts, or strictures
  • This class will not be discussed here

Intrahepatic Cholestasis (IHC)

  • Hepatocellular functional defects or presence of obstructive lesions in the intrahepatic biliary tract distal from bile canaliculi resulting to cholestasis
  • Chronic (lasts >6 months) cholestatic diseases are commonly intrahepatic

Signs and Symptoms

  • Fatigue
  • Pruritus
  • Jaundice
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Stephen Padilla, 6 days ago
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.